A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Seagen Inc.
Compass Therapeutics
BioNTech SE
Astellas Pharma Inc
PDS Biotechnology Corp.
Inhibrx Biosciences, Inc
Bicara Therapeutics
Dragonfly Therapeutics
PMV Pharmaceuticals, Inc
Hoffmann-La Roche
Tizona Therapeutics, Inc
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Cue Biopharma
VLP Therapeutics
Novartis
Inhibrx Biosciences, Inc
VM Oncology, LLC
Incyte Corporation
PDS Biotechnology Corp.
BioAtla, Inc.
Hookipa Biotech GmbH
Hookipa Biotech GmbH
Merck Sharp & Dohme LLC
Bicara Therapeutics
MacroGenics
Incyte Corporation
ALX Oncology Inc.
ALX Oncology Inc.
Ascendis Pharma A/S
Merck Sharp & Dohme LLC
Hookipa Biotech GmbH
DEKA Biosciences
Rapa Therapeutics LLC
Regeneron Pharmaceuticals
Intensity Therapeutics, Inc.
Alentis Therapeutics AG
Psivac Ltd
Presage Biosciences
Carisma Therapeutics Inc
NextCure, Inc.
Atara Biotherapeutics
Rakuten Medical, Inc.
Inhibrx Biosciences, Inc
GlaxoSmithKline
GlaxoSmithKline
iTeos Therapeutics
Bayer
Presage Biosciences